← FDA DRUG APPROVALS

FDA ANDA · ANDA204724

SEVELAMER HYDROCHLORIDE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA204724
TYPE
ANDA
ORIGINAL APPROVAL
2019-02-08
LATEST ACTION
2019-02-08
ROUTE
ORAL, PARENTERAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SEVELAMER HYDROCHLORIDEPrescription
SEVELAMER HYDROCHLORIDE 800MG · TABLET · ORAL
SEVELAMER HYDROCHLORIDEPrescription
SEVELAMER HYDROCHLORIDE 400MG · TABLET · ORAL

Approval history

2019-02-08UNKNOWN · Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →